Humana Says Acthar's Meteoric Price Hike Cost It $700M

By Nadia Dreid · August 9, 2019, 10:09 PM EDT

Mallinckrodt ran "one of the most outrageous price-gouging schemes in the history of American medicine" on its hormone gel used primarily to treat an infant seizure syndrome, according to a new...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Humana, Inc. v. Mallinckrodt ARD LLC et al

Case Number

2:19-cv-06926

Court

California Central

Nature of Suit

Anti-Trust

Date Filed

August 08, 2019